


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of claims:

1. (currently amended) An A_1 AdoR antagonist that is a 1,3 dipropylxanthine with an ester function at the 8-position, wherein the ester function is a cycloalkyl substituted with $-\text{COOR}_1$ and wherein R_1 is alkyl, provided that the cycloalkyl is not cyclohexyl when R_1 is methyl.
2. (canceled)
3. (currently amended) The compound, according to claim 1, wherein said ester function has a structure selected from the group consisting of:





and salts thereof; wherein R_1 is alkyl.

4. (currently amended) A pharmaceutical composition comprising an A_1 AdoR antagonist that is a 1,3 dipropylxanthine with an ester function at the 8-position, wherein the ester function is a cycloalkyl substituted with $-\text{COOR}_1$ and wherein R_1 is alkyl, provided that the cycloalkyl is not cyclohexyl when R_1 is methyl.

5. (canceled)


6. (previously presented) The pharmaceutical composition, according to claim 4, wherein said ester of function has a structure selected from the group consisting of:






and salts thereof; where an R_1 is alkyl.

10. (original) The method, according to claim 7, wherein the individual is a human.
11. (canceled)
12. (new) An A_1AdoR antagonist that is a 1,3 dipropylxanthine with an ester function at the 8-position, wherein the ester function has a structure selected from the group consisting of:




and salts thereof; wherein R_1 is alkyl.

13. (new) A pharmaceutical composition comprising an A_1AdoR antagonist that is a 1,3 dipropylxanthine with an ester function at the 8-position, wherein the ester function has a structure selected from the group consisting of:



and salts thereof; wherein R_1 is alkyl.

14. (new) A method for treating congestive heart failure in an individual wherein said method comprises administering to said individual effective amount of a pharmaceutical composition comprising an A₁AdoR antagonist that is a 1,3-propylxanthine with an ester function at the 8-position, wherein the ester function has a structure selected from the group consisting of:



and salts thereof; wherein R₁ is alkyl.

15. (new) The method according to claim 14 wherein the individual is a human.